Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

  title={Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.},
  author={Yong He},
  journal={The New England journal of medicine},
  volume={373 6},
n engl j med 373;6 august 6, 2015 578 ScvO2 (because ScvO2 data were not available for the usual-care groups), showed no evidence of benefit. We agree with Priebe that administration of intravenous isotonic saline solutions can cause hyperchloremia and acidosis. In the ProMISe trial, although we did not record the type of crystalloid administered or the serum chloride level, the volume of crystalloid administered by 72 hours after randomization was similar in the EGDT and usual-care… CONTINUE READING
Highly Influential
This paper has highly influenced 18 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 20 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 245 extracted citations

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2017
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-4 of 4 references

Rociletinib in EGFR - mutated non – small - cell lung cancer

LV Sequist, JC Soria, JW Goldman
N Engl J Med • 2001

Similar Papers

Loading similar papers…